Vimarsana
Biggest News Aggregation in the World

Page 23 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Access Program Today - Breaking & Trending Today

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates - Vimarsana News

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates

Published: November 7, 2022

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...

Source: prnewswire.com
Related Topics:
United StatesNew YorkState Of New YorkDror Ben AsherRedhill BiopharmaAdi FrishKukbo CoUniversity Of TennesseeRedhill Biopharma LtdDevelopment ExpensesCompany Annual Report On FormTrademark OfficeCompany Expanded Access ProgramRedhill IncPrnewswire Redhill Biopharma LtdCenters For DiseaseCompany American Depositary Shares AdssCantor Fitzgerald CoEuropean CommissionZinsight TechnologyExchange CommissionSupreme CourtBusiness DevelopmentHill BiopharmaChief Executive Officer
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates - Vimarsana News

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates

Published: November 7, 2022

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...

Source: prnewswire.com
Related Topics:
United StatesNew YorkState Of New YorkDror Ben AsherRedhill BiopharmaAdi FrishKukbo CoUniversity Of TennesseeRedhill Biopharma LtdDevelopment ExpensesCompany Annual Report On FormTrademark OfficeCompany Expanded Access ProgramRedhill IncPrnewswire Redhill Biopharma LtdCenters For DiseaseCompany American Depositary Shares AdssCantor Fitzgerald CoEuropean CommissionZinsight TechnologyExchange CommissionSupreme CourtBusiness DevelopmentHill BiopharmaChief Executive Officer
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated2 to be between $16.5 million to $18.5 million; Operating loss estimated to be in the range of $5.5 million to $7.5 million; Q3/22 cash flow from operating activities is estimated positive for U.S. operations, before interest payments3 -- Commercial update: Upward trajectory continues with Talic - Vimarsana News

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net revenues of $13.1 million; Q3/22: Net revenues estimated2 to be between $16.5 million to $18.5 million; Operating loss estimated to be in the range of $5.5 million to $7.5 million; Q3/22 cash flow from operating activities is estimated positive for U.S. operations, before interest payments3 -- Commercial update: Upward trajectory continues with Talic

Published: November 7, 2022

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net... | November 7, 2022

Source: marketscreener.com
Related Topics:
United StatesNew YorkState Of New YorkDror Ben AsherRedhill BiopharmaAdi FrishKukbo CoUniversity Of TennesseeRedhill Biopharma LtdDevelopment ExpensesCompany Annual Report On FormTrademark OfficeCompany Expanded Access ProgramRedhill IncCenters For DiseaseCompany American Depositary Shares AdssCantor Fitzgerald CoEuropean CommissionZinsight TechnologyExchange CommissionSupreme CourtBusiness DevelopmentChief Executive OfficerAdministrative ExpensesCash Used
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates - Vimarsana News

RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates

Published: November 7, 2022

Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:...

Source: prnewswire.com
Related Topics:
United StatesNew YorkState Of New YorkDror Ben AsherRedhill BiopharmaAdi FrishKukbo CoUniversity Of TennesseeRedhill Biopharma LtdDevelopment ExpensesCompany Annual Report On FormTrademark OfficeCompany Expanded Access ProgramRedhill IncPrnewswire Redhill Biopharma LtdCenters For DiseaseCompany American Depositary Shares AdssCantor Fitzgerald CoEuropean CommissionZinsight TechnologyExchange CommissionSupreme CourtBusiness DevelopmentHill BiopharmaChief Executive Officer
RedHill Presents New Talicia® Data Analyses at Obesity Week 2022 - Vimarsana News

RedHill Presents New Talicia® Data Analyses at Obesity Week 2022

Published: November 4, 2022

Talicia's efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI);...

Source: prnewswire.com
Related Topics:
United StatesRedhill BiopharmaAdi FrishDana PortenierDuke University School Of MedicineNational Cancer InstituteWorld Health OrganizationAmerican Diabetes AssociationNational Diabetes StatisticsDivision Of MetabolicRedhill Biopharma LtdCompany Annual Report On FormExchange CommissionEnd Results ProgramDivision Of NutritionCompany Expanded Access ProgramCorporate Business DevelopmentAdverse Reactions To Redhill Biopharma IncHill BiopharmaObesity Week Annual MeetingPhysiologically Based PharmacokineticDivision ChiefWeight Loss SurgeryDuke University SchoolPrescribing Informationfor